Mosaic Family Wealth Partners LLC Purchases 7,228 Shares of Merck & Co., Inc. $MRK

Mosaic Family Wealth Partners LLC boosted its position in Merck & Co., Inc. (NYSE:MRK) by 154.6% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 11,904 shares of the company’s stock after purchasing an additional 7,228 shares during the quarter. Mosaic Family Wealth Partners LLC’s holdings in Merck & Co., Inc. were worth $1,530,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Donaldson Capital Management LLC grew its position in shares of Merck & Co., Inc. by 1.7% in the 2nd quarter. Donaldson Capital Management LLC now owns 798,673 shares of the company’s stock worth $102,630,000 after buying an additional 13,513 shares during the last quarter. AlTi Global Inc. lifted its position in Merck & Co., Inc. by 2.9% during the second quarter. AlTi Global Inc. now owns 24,188 shares of the company’s stock valued at $3,128,000 after acquiring an additional 674 shares during the last quarter. HighTower Advisors LLC boosted its stake in Merck & Co., Inc. by 1.2% in the second quarter. HighTower Advisors LLC now owns 3,679,920 shares of the company’s stock valued at $472,870,000 after acquiring an additional 44,516 shares in the last quarter. Advisor OS LLC boosted its stake in Merck & Co., Inc. by 1.7% in the second quarter. Advisor OS LLC now owns 36,859 shares of the company’s stock valued at $4,736,000 after acquiring an additional 613 shares in the last quarter. Finally, TBH Global Asset Management LLC grew its holdings in Merck & Co., Inc. by 15.8% in the second quarter. TBH Global Asset Management LLC now owns 2,984 shares of the company’s stock worth $383,000 after purchasing an additional 408 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors.

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP David R. Maraldo sold 18,706 shares of the stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the transaction, the executive vice president directly owned 18,212 shares of the company’s stock, valued at $2,344,248.64. This trade represents a 50.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP David Michael Williams sold 52,847 shares of the firm’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the transaction, the executive vice president owned 31,716 shares in the company, valued at $4,084,069.32. The trade was a 62.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 228,238 shares of company stock worth $29,977,783 over the last quarter. Company insiders own 0.17% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. JPMorgan Chase & Co. increased their price objective on Merck & Co., Inc. from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Barclays upped their target price on Merck & Co., Inc. from $140.00 to $150.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Morgan Stanley upgraded Merck & Co., Inc. from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $116.00 to $179.00 in a research note on Thursday. Royal Bank Of Canada downgraded Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and raised their price target for the stock from $142.00 to $150.00 in a report on Thursday. Finally, Guggenheim boosted their price target on Merck & Co., Inc. from $145.00 to $146.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Fifteen investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and a consensus target price of $144.10.

Merck & Co., Inc. Price Performance

Shares of MRK opened at $152.43 on Monday. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The company’s fifty day moving average price is $128.09 and its 200-day moving average price is $121.29. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $154.49. The firm has a market capitalization of $376.07 billion, a PE ratio of 121.94, a price-to-earnings-growth ratio of 6.40 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same period in the prior year, the company earned $2.13 earnings per share. The company’s revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities research analysts predict that Merck & Co., Inc. will post 2.76 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a $0.85 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.2%. Merck & Co., Inc.’s payout ratio is presently 272.00%.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their personalized cancer therapy met key Phase 3 goals, improving recurrence-free and distant metastasis-free survival for high-risk melanoma patients when added to Keytruda. The result is the first major late-stage win for an mRNA cancer vaccine and strengthens the potential for regulatory approval and broader oncology applications. MRK/MRNA’s Personalized Cancer Therapy Delivers First Phase III Win
• Positive Sentiment: Several Wall Street firms raised their outlooks for MRK: Goldman Sachs increased its price target to $160 and kept a Buy rating, while BMO raised its target to $170 and UBS lifted its target to $175. Morgan Stanley also upgraded the shares to Overweight with a $179 target after the cancer-trial success.
• Positive Sentiment: Investors see Merck’s newer products, acquired assets and pipeline programs as a potential growth cushion against Keytruda’s eventual patent expiration. The company’s expanding portfolio could help diversify revenue beyond its flagship drug. Can Merck’s New Drugs Offer Growth Cushion Ahead of Keytruda LOE?
• Neutral Sentiment: Unusually high options activity indicates heightened investor interest and potential volatility, but it does not by itself establish the direction of the stock.
• Negative Sentiment: RBC Capital Markets downgraded Merck to Sector Perform and set a $150 target, arguing that execution risks and the 2028 Keytruda loss of exclusivity are being underestimated. RBC said near-term catalysts are attractive, but the stock’s valuation leaves limited room for additional gains. Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
• Negative Sentiment: Jefferies separately moved Merck from Strong Buy to Hold. The central concern is that the shares have already rallied substantially on the trial news, making the current valuation appear demanding relative to the remaining patent and execution risks.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.